Abstract:Purpose: The aim of this study is to compare the blood oxygen level–dependent (BOLD) fluctuation power in 96 frequency points ranging from 0 to 0.25 Hz between benign and malignant musculoskeletal (MSK) tumors via power spectrum analyses using functional magnetic resonance imaging (fMRI). Materials and methods: BOLD-fMRI and T1-weighted imaging (T1WI) of 92 patients with benign or malignant MSK tumors were acquired by 1.5-T magnetic resonance scanner. For each patient, the tumor-related BOLD time series were extracted, and then, the power spectrum of BOLD time series was calculated and was then divided into 96 frequency points. A two-sample t -test was used to assess whether there was a significant difference in the powers (the "power" is the square of the BOLD fluctuation amplitude with arbitrary unit) of each frequency point between benign and malignant MSK tumors. The receiver operator characteristic (ROC) analysis was used to assess the diagnostic capability of distinguishing between benign and malignant MSK tumors. Results: The result of the two-sample t -test showed that there was significant difference in the power between benign and malignant MSK tumor at frequency points of 58 (0.1508 Hz, P = 0.036), 59 (0.1534 Hz, P = 0.032), and 95 (0.247 Hz, P = 0.014), respectively. The ROC analysis of mean power of three frequency points showed that the area of under curve is 0.706 ( P = 0.009), and the cutoff value is 0.73130. If the power of the tumor greater than or equal to 0.73130 is considered the possibility of benign tumor, then the diagnostic sensitivity and specificity values are 83% and 59%, respectively. The post hoc analysis showed that the merged power of 0.1508 and 0.1534 Hz in benign MSK tumors was significantly higher than that in malignant ones ( P = 0.014). The ROC analysis showed that, if the benign MSK tumor was diagnosed with the power greater than or equal to the cutoff value of 1.41241, then the sensitivity and specificity were 67% and 68%, respectively. Conclusion: The mean power of three frequency points at 0.1508, 0.1534, and 0.247 Hz may potentially be a biomarker to differentiate benign from malignant MSK tumors. By combining the power of 0.1508 and 0.1534 Hz, we could better detect the difference between benign and malignant MSK tumors with higher specificity.

Histopathologic and Clinical Correlation of Aberrant Neuromagnetic Activities with Low to High Frequency of Gliomas

Motor network plasticity and low-frequency oscillations abnormalities in patients with brain gliomas: a functional MRI study.

Stratification of Grade of Spinal Cord Non-Ependymal Gliomas by Magnetic Resonance Imaging.

The Application of Multi-Voxel Magnetic Resonance Spectroscopy in Differentiating Gliomas from Solitary Intracranial Metastases

Clinical Assessment of Magnetic Resonance Spectroscopy and Diffusion-Weighted Imaging in Diffuse Glioma: Insights Into Histological Grading and IDH Classification

Resting state brain activity in patients with migraine: a magnetoencephalography study

Study of 1H-Magnetic Resonance Spectroscopy in the Peritumoral Edema of Astrocytomas in Brain

Noninvasive Evaluation of Cerebral Glioma Grade by Using Multivoxel 3D Proton MR Spectroscopy.

Magnetic Resonance Spectroscopic and Perfusion MRI in High Grade Gliomas and Metastases

Noninvasively Evaluating the Grading of Glioma by Multiparametric Magnetic Resonance Imaging

Correlation of ~1HMRS imaging and proliferative activity in the tumor and peritumoral zone of gliomas.

Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index

Prognostic Value of Magnetic Resonance Imaging Features in Low-Grade Gliomas

1H-MR spectroscopy in grading of cerebral glioma: A new view point, MRS image quality assessment

Assessing the Predictability of the H3K27M Status in Diffuse Glioma Patients Using Frequency Importance Analysis on Chemical Exchange Saturation Transfer MRI.

Comparing the blood oxygen level–dependent fluctuation power of benign and malignant musculoskeletal tumors using functional magnetic resonance imaging

Gliomas findings on proton magnetic resonane spectroscopy imaging and its clinical application

Cerebrovascular Dysregulation in Patients with Glioma Assessed with Time-shifted BOLD Fmri

Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma

Individual structural abnormality indexes are associated with molecular, histological and cognitive indicators for glioma patients Running title:Anoninvasive way to glioma malignancy

Quantitative Analysis of Mean Apparent Propagator-Magnetic Resonance Imaging for Distinguishing Glioblastoma from Solitary Brain Metastasis